Research programme: antiviral agents - ConjuChem
Alternative Names: DAC™:HIVLatest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator ConjuChem Biotechnologies
- Developer ConjuChem
- Class Peptides
- Mechanism of Action Viral fusion protein inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral, Injection)
- 16 Sep 2011 Research programme: antiviral agents - ConjuChem is available for partnering as of 16 Sep 2011. http://www.conjuchem.com
- 30 Aug 2011 Preclinical development is ongoing in USA